NCT01513200View on ClinicalTrials.gov

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

Unfractionated heparin (UFH)

UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours

DRUG

Bendavia

Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours

DRUG

Saline (0.9%, sterile, for infusion)

Saline (placebo) Constant IV infusion for 4 hours

Trial Locations (1)

33014-3616

Clinical Pharmacology of Miami, Miami

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT01513200 - Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia | Biotech Hunter | Biotech Hunter